WO2008058234A3 - Pharmaceutical formulations for 1,4-dihyrdropyridine compounds having improved solubility - Google Patents
Pharmaceutical formulations for 1,4-dihyrdropyridine compounds having improved solubility Download PDFInfo
- Publication number
- WO2008058234A3 WO2008058234A3 PCT/US2007/084068 US2007084068W WO2008058234A3 WO 2008058234 A3 WO2008058234 A3 WO 2008058234A3 US 2007084068 W US2007084068 W US 2007084068W WO 2008058234 A3 WO2008058234 A3 WO 2008058234A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dihyrdropyridine
- compounds
- pharmaceutical formulations
- improved solubility
- approximately
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
A pharmaceutical composition comprising a 1,4-dihydropyridine pharmaceutical agent, particularly (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate), a mixture of glycerol and PEG1500 esters of long fatty acids having a melting point of approximately 44 °C and a hydrophilic/lipophilic balance of approximately 14 (Gelucire 44/14) and d-alpha-tocopheryl polyethylene glycol 1000 succinate (Vitamin E TPGS), and further optionally comprising polyethylene glycol-15-hydroxystearate (Solutol-HS 15) and/or polyoxyl castor oil (Cremophor-EL), exhibits enhanced solubility characteristics.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85750406P | 2006-11-08 | 2006-11-08 | |
US60/857,504 | 2006-11-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008058234A2 WO2008058234A2 (en) | 2008-05-15 |
WO2008058234A3 true WO2008058234A3 (en) | 2008-06-26 |
Family
ID=39365371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/084068 WO2008058234A2 (en) | 2006-11-08 | 2007-11-08 | Pharmaceutical formulations for 1,4-dihyrdropyridine compounds having improved solubility |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008058234A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150064232A (en) | 2007-05-25 | 2015-06-10 | 더 유니버시티 오브 브리티쉬 콜롬비아 | Formulations for the oral administration of therapeutic agents and related methods |
KR20110056516A (en) | 2008-09-12 | 2011-05-30 | 크리티컬 파머수티컬스 리미티드 | Improvements in the absorption of therapeutic agents across mucosal membranes or the skin |
WO2011050457A1 (en) | 2009-10-26 | 2011-05-05 | The University Of British Columbia | Stabilized formulation for oral administration of therapeutic agents and related methods |
US20150250750A1 (en) * | 2012-10-16 | 2015-09-10 | Wockhardt Limited | Pharmaceutical compostions of diclofenac or salts thereof |
CN106689775A (en) * | 2015-11-12 | 2017-05-24 | 北京鑫华乐源科技发展有限公司 | Production method of feed used for producing eggs rich in xanthophyll and alpha-linolenic acid |
WO2019052471A1 (en) * | 2017-09-12 | 2019-03-21 | 北京福纳康生物技术有限公司 | Fullerene composition and preparation method and use thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5665740A (en) * | 1993-12-10 | 1997-09-09 | Bayer Aktiengesellschaft | Isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1, 4-dihydro-2,6-dimethyl-pyridine-3,5-dica rboxylate |
US6531139B1 (en) * | 1997-07-29 | 2003-03-11 | Pharmacia & Upjohn Company | Self-emulsifying formulation for lipophilic compounds |
US6579898B2 (en) * | 2001-03-01 | 2003-06-17 | Pfizer Inc. | Compositions having improved bioavailability |
US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
US7030155B2 (en) * | 1998-06-05 | 2006-04-18 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
-
2007
- 2007-11-08 WO PCT/US2007/084068 patent/WO2008058234A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5665740A (en) * | 1993-12-10 | 1997-09-09 | Bayer Aktiengesellschaft | Isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1, 4-dihydro-2,6-dimethyl-pyridine-3,5-dica rboxylate |
US6531139B1 (en) * | 1997-07-29 | 2003-03-11 | Pharmacia & Upjohn Company | Self-emulsifying formulation for lipophilic compounds |
US7030155B2 (en) * | 1998-06-05 | 2006-04-18 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
US6579898B2 (en) * | 2001-03-01 | 2003-06-17 | Pfizer Inc. | Compositions having improved bioavailability |
Also Published As
Publication number | Publication date |
---|---|
WO2008058234A2 (en) | 2008-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008058234A3 (en) | Pharmaceutical formulations for 1,4-dihyrdropyridine compounds having improved solubility | |
HUP0500843A2 (en) | Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability | |
EP0999826B1 (en) | Self-emulsifying formulation for lipophilic compounds | |
EP1903866B1 (en) | Improved delivery of tetrahydrocannabinol | |
WO2005063218A3 (en) | Pharmaceutical formulations of bisphosphonates | |
JP2007508296A5 (en) | ||
WO2005110398A3 (en) | Pharmaceutical solution formulations containing 17-aag | |
WO2008120711A1 (en) | Tamibarotene capsule preparation | |
US11116744B2 (en) | Pharmaceutical composition for oral administration comprising taxane | |
EP1894567A4 (en) | Concomitant pharmaceutical agents and use thereof | |
JP2009529531A (en) | Coated capsule containing pharmaceutical ingredients | |
ATE398997T1 (en) | SELF-NANOEMULSIFIING OILY FORMULATION FOR ADMINISTRATION OF POORLY WATER-SOLUBLE MEDICINAL PRODUCTS | |
MA30759B1 (en) | PHARMACEUTICAL COMPOSITION | |
CA2478424A1 (en) | Self emulsifying drug delivery systems for poorly soluble drugs | |
KR102656954B1 (en) | Oral taxane compositions and methods | |
WO2007100614A3 (en) | STABLE NON-CRYSTALLINE FORMULATION COMPRISING HMG-CoA REDUCTASE INHIBITOR | |
JP2009132712A5 (en) | ||
JP6484393B2 (en) | Pharmaceutical composition containing dutasteride and capsule preparation containing the same | |
WO2001093816A3 (en) | Stabilized compositions containing oxygen-labile active agents | |
KR910016332A (en) | Pharmaceutical compositions containing poorly water-soluble drugs | |
CA2690490A1 (en) | Pharmaceutical formulations of loratadine for encapsulation and combinations thereof | |
PE20060946A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING LERCANIDIPINE | |
MXPA04000535A (en) | Antihistamine formulations for soft capsule dosage forms. | |
WO2019081451A1 (en) | Liquid filled formulations of pde5 inhibitors | |
KR20100064370A (en) | Antifungal composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07864098 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07864098 Country of ref document: EP Kind code of ref document: A2 |